J1 👨‍👩‍👦‍👦 🇮🇹 🇺🇸 🇧🇪

1.7K posts

J1 👨‍👩‍👦‍👦 🇮🇹 🇺🇸 🇧🇪 banner
J1 👨‍👩‍👦‍👦 🇮🇹 🇺🇸 🇧🇪

J1 👨‍👩‍👦‍👦 🇮🇹 🇺🇸 🇧🇪

@blessedpapa73

Espatriato. Liberista selvatico. Travel addict. Tifoso emotivo dei Niners. 🇮🇹🇺🇸🇧🇪

Brussels, Belgium Katılım Temmuz 2018
60 Takip Edilen29 Takipçiler
Kelly
Kelly@SelfMadeMastery·
Do I have any followers who actually got in early to $SNDK?
English
15
0
20
6K
M. V. Cunha
M. V. Cunha@mvcinvesting·
🚨 JUST IN: $IREN and NVIDIA announced a strategic partnership to accelerate the deployment of up to 5 GW of AI infrastructure. NVIDIA has a five-year right to purchase up to 30M shares of $IREN at $70 per share, a potential investment of up to $2.1B. Congrats bulls!
M. V. Cunha tweet media
English
45
111
1.5K
165.2K
BIOTECH SCANNER
BIOTECH SCANNER@BIOTECHSCANNER·
$IOVA - IOVA should be up 15% today. But people are gambling with a biotech that just got a CRL and going bankrupt. This is why 90% of retail traders lose money. Someone just shared a screenshot of Kai whom I have blocked long ago is threatening to walking away from this ticker. Oh hell. What are we going to do now 🤣. Patience my friends. This is the one.
English
12
2
66
4.6K
Luca Bottura
Luca Bottura@bravimabasta·
In questi giorni stiamo scoprendo perché, alla fine, le energie rinnovabili sono preferibili al fossile: il sole, il vento e l’acqua non li puoi bombardare.
Italiano
372
164
1.4K
92.2K
BIOTECH SCANNER
BIOTECH SCANNER@BIOTECHSCANNER·
First day of Spring Break for daughter. Will be off for several days.
GIF
English
5
1
37
2.1K
Varun Malhotra
Varun Malhotra@varuninvesting·
I have fallen for 2) 3) and 7) What about you?
English
8
0
6
3K
Varun Malhotra
Varun Malhotra@varuninvesting·
Low P/E traps catch beginners. These 8 catch smart investors. I've fallen for at least 3. (1) "Down 84%, must be cheap" $DUOL $545 to $89. Last night. FCF went from $43M to $360M in three years. Revenue +35%. Beat earnings. 50M users. $1B cash. $400M buyback announced. And you still lost 84%. Here's the question nobody buying the dip is asking: can you imagine a world without Duolingo in 5 years? I can. ChatGPT teaches languages. Google teaches languages. The moat might be shrinking while the financials look great. "FCF is growing" doesn't help when you paid 150x for it. And it really doesn't help if the moat is deteriorating while the cash flow isn't. (2) Buying what Buffett buys $OXY Berkshire takes a position. You follow. Except Berkshire got preferred shares with an 8% coupon, warrants at a strike below your entry, and board influence you will never have. You bought the same company with worse terms and no leverage. You're not following the trade. You're the exit liquidity. (3) "The Amazon of Southeast Asia" $SE You find the dominant platform of another country. You anchor on the developed-market comp's multiples. "If Amazon is worth $2T, the Amazon of Southeast Asia must be worth X." Sea Limited went from $370 to $35. The analogy does the analysis for you. That's the trap. (4) The acquirer's curse $PYPL Dominant brand. Network effects. 400M+ accounts. Then management overpaid $4B for Honey, launched a dozen unfocused initiatives, and lost strategic clarity while Stripe, Apple Pay, and Block attacked from every direction. Stock went from $300 to $60. Revenue grew the entire time. (5) Platform shift denial $ADBE 90%+ recurring revenue. Creative software monopoly. You buy at 45x because the moat looks permanent. Then AI shows up. Adobe wasn't disrupted. Revenue kept growing. But at 45x you need certainty, and AI removed it. Stock goes from $700 to $350. At 45x, "the moat is probably fine" loses you half your money. (6) The fake compounder $EVO High ROIC. Asset-light. 70% EBITDA margins. 43% revenue CAGR. You build the DCF. You size the position. Growth decelerates to single digits. Regulatory risk surfaces. Stock goes from 40x to 14x. This one doesn't catch lazy investors. It catches the ones who did the work. (7) The conglomerate discount $BABA SOTP says 40-60% upside. Alibaba has traded at 8-12x for five years. Management has tried. Buybacks, restructuring, Cainiao IPO. The discount still won't close. You don't control the timeline. And the Chinese government can intervene at any point for any reason. That's not a risk you can model. When the discount requires a government to stay out of the way, the discount IS the valuation. (8) Quality at any price $COST 52x forward earnings. The business is genuinely world-class. Membership renewals above 90%. But you've paid for 10 years of growth upfront. If Costco grows 12% annually and the P/E compresses to 30x, your annualized return is about 5%. You bought a great business and earned a treasury bill. Munger said wonderful company at a fair price. Not wonderful company at any price. Cheap on a screener. Expensive in your portfolio. I've owned 3 of these. The tuition was expensive.
Varun Malhotra tweet media
English
59
47
435
60.1K
BIOTECH SCANNER
BIOTECH SCANNER@BIOTECHSCANNER·
$IOVA - It’s all under our noses the entire time. IF YOU CONNECT THE DOTS. If you listened to shorts on Stocktwits, you’d have missed the whole thing and actually losing your precious shares. This launch is similar to what happened with ARQT and their Zoryve launch. Took a while then 🚀 $8 to $31 in less than a year. $IOVA has 10X the potential of ARQT from here.
BIOTECH SCANNER@BIOTECHSCANNER

$IOVA - I don’t know how earnings will be but if you connect these dots, shorts maybe roasted tomorrow. 1. 5 year retrospective data showing amazing efficacy that was even better than clinical trials especially in patients who had two or fewer lines of treatments. 2. Key opinion leaders encouraging their peers to treat their patients with Amtagvi as soon as they progress from frontline. This is consistent with the National Comprehensive Cancer Network (NCCN). It is a not-for-profit alliance of 33 leading cancer centers such as MD Anderson, Memorial Sloan Kettering, and Mayo Clinic.  The NCCN is widely considered the gold standard for cancer care because it develops the most frequently updated clinical practice guidelines in medicine.  3. Hirings: So many sales related positions were posted. This is shortly after the downsizing of 19%. Companies don’t start rehiring like this unless serious demand increases. 4. Another retrospective study shows greater efficacy for patients who received commercial Amtagvi (not clinical trial) reconfirms the 5 year retrospective study reported earlier last year. 5. More community hospitals and ATCs are coming and proudly announcing availability for TIL treatment. This will generate lots of revenue for hospitals AND $IOVA 6. Management has been EXTREMELY active at conferences. They are spreading the great news about Amtagvi and the next generation TIL. 7. Earnings being released in the morning. I was the first person to catch the change of time for earnings last quarter and I predicted earnings for Q3 would be good and it was. I believe this earnings report will even be better. Shorts will be roasted. 7. If $IOVA releases positive results on IOV-4001 the next Monday on March 2, shorts will be cooked I may not sleep at all. I may watch the men’s USA vs Canada hockey game over and over again. 😝

English
4
3
40
4.4K
BIOTECH SCANNER
BIOTECH SCANNER@BIOTECHSCANNER·
@CJoMaher Possibly a wife changing event! I mean life changing. My bad 😂
English
4
0
6
287
BIOTECH SCANNER
BIOTECH SCANNER@BIOTECHSCANNER·
$IOVA - Management said approximately $12B in potential annual sales for melanoma, NSCLC and sarcoma with Amtagvi in the US ALONE!!! Sell and you will cry later. This is a monster in the making. I have said this many times. Worth repeating!
English
9
13
105
11.7K
2outted
2outted@2outted·
$GOSS huge bounce coming here, after the freakout is over
English
1
0
8
1.4K
Pete de mountain
Pete de mountain@Petedemountain·
@blessedpapa73 @micheleboldrin Io non ho detto nulla di tutto ciò che lei mi attribuisce. Ho solo scritto che non aveva capito quanto scritto da Boldrin. Lo sa che attribuire ad altri cose che non hanno detto è una chiara manifestazione di disonestà intelletuale? Inutile, Lei proprio non ce la fa...
Italiano
1
0
0
74
Michele Boldrin
Michele Boldrin@micheleboldrin·
Costo aziendale per uno stipendio netto di 200mila in tre diverse città italiane. Commentare.
Michele Boldrin tweet media
Italiano
31
15
272
50.8K
Michele Boldrin
Michele Boldrin@micheleboldrin·
Per me puoi mandarmi tutti gli score che vuoi ed anche uno in piu'. Rimangono due fatti - in questo scambio nemmeno comprendi quello che c'e' scritto ... forse era un brutto momento, chissa'? - Sei anonimo e quando gli anonimi la sparano grossa ma poi evitano il confronto pubblico una ragione c'e': che l'hanno sparata piu' grossa di quella che riuscirebbero a provare. Up to you to prove me wrong.
Italiano
4
0
6
449
Pete de mountain
Pete de mountain@Petedemountain·
@blessedpapa73 @micheleboldrin Tipico. Quando mancano gli argomenti, quando si sentono dialetticamente sconfitti, passano agli insulti personali. Continui pure: i suoi tweet entrano nella mia indagine sociologica. Sono davvero curioso di scoprire di quanto ridicolo si coprirà ancora. Vada, vada pure...
GIF
Italiano
1
0
2
68
Biotech Autist
Biotech Autist@BiotechAutist·
I am now short $VNDA. I do not think fda will approve.
English
22
0
11
6.6K
Pete de mountain
Pete de mountain@Petedemountain·
@blessedpapa73 @micheleboldrin Irrilevanti i suoi score. Che lei non sa comprendere un testo scritto è sotto gli occhi di tutti. Sorprendente che lei non comprenda quanto si sta rendendo ridicolo; a maggior ragione cone questi commenti da "son l'anonimo con il pene più grosso". Buona vita davvero.
Italiano
1
0
7
128
Pete de mountain
Pete de mountain@Petedemountain·
@blessedpapa73 @micheleboldrin Sì, me le godo, non si preoccupi. La ringrazio per aver fornito al pubblico una ulteriore conferma delle sue abilità di comprensione del testo. Buona vita.
Italiano
1
0
7
261